Venture investors put $16.3 billion into 235 biopharma rounds in the first half of 2026, and 13 biotech IPOs raised $5.0 billion — more than any full-year total from 2022 through 2025, according to J.P. Morgan. Below are the size forecasts, regional shares, funding flows, FDA approvals, pipeline counts and company revenues behind those numbers, each with its period and source.
Biotechnology Market
How Big Is The Biotechnology Market In 2026?
Five research firms publish current estimates, and their 2025 base years run from $1,376.1 billion to $1.85 trillion.
Growth rates sit much closer together, between 12.5% and 14.3%. The firms count different things: Precedence Research splits the market into bio-pharmacy, bio-industries, bio-services, bio-agriculture and bio-informatics, while Polaris Market Research segments by technology and puts DNA sequencing alone at 38.75% of its 2025 total.
| Research firm | 2025 value | 2026 value | Forecast | CAGR |
|---|---|---|---|---|
| Polaris Market Research | $1.85 trillion | not stated | through 2034 | 13.5% |
| Precedence Research | $1.77 trillion | $2.02 trillion | $6.34T by 2035 | 13.61% |
| Towards Healthcare | $1,744.83 billion | $1,962.93 billion | $5,666.02B by 2035 | 12.5% |
| Straits Research | not stated | $1,870 billion | $5,220B by 2034 | 13.67% |
| Fortune Business Insights | $1,376.1 billion | $1,491.5 billion | $4,334.8B by 2034 | 14.3% |
Source: Precedence Research, Polaris Market Research, Towards Healthcare, Straits Research and Fortune Business Insights, 2026 report editions. Each row is that firm’s own vendor-revenue estimate under its own scope definition; CAGRs run from 2026 to the stated end year.
Which Region Leads The Biotechnology Market?
North America tops every published regional split, though the size of its lead depends on the firm.
| Research firm | North America share of 2025 revenue |
|---|---|
| Fortune Business Insights | 43.34% |
| Polaris Market Research | 42.30% |
| Straits Research | 42.17% |
| Precedence Research | 37.42% |
Source: Fortune Business Insights, Polaris Market Research, Straits Research and Precedence Research, 2026 report editions; each share is measured against that firm’s own global total for 2025.
Fortune Business Insights values North America at $596.5 billion for 2025. Precedence Research sizes the United States alone at $316.41 billion in 2025, rising to $361.07 billion in 2026.
Asia Pacific is named the fastest-growing region by both firms that state a rate: 14.8% a year from 2026 to 2035 at Precedence Research, and 10.85% at Polaris Market Research.
Biotechnology Market Revenue By Application
Bio-pharmacy took 42% of biotechnology revenue in 2025, the largest application share Precedence Research reports. Bio-informatics is the firm’s fastest-growing application at 13.2% a year through 2035.
The chart below plots the same firm’s published revenue by application for 2022 through 2024, the last three years it reports in dollars rather than shares.
Source: Precedence Research, Biotechnology Market report, revenue by application 2022–2024.
By technology, tissue engineering and regeneration held the biggest slice at 19.17% in 2025, with chromatography growing fastest at 15.1% a year through 2035.
Bio-services covers the contract research and manufacturing layer, home to firms such as Swiss contract manufacturer Lonza and clinical-trial services group IQVIA. It is the smallest of the five applications at $107.38 billion in 2024.
How Much Funding Does The Biotechnology Market Attract?
Biopharma venture funding fell for a second year in 2025. J.P. Morgan counted 413 rounds worth $24.6 billion, against 461 rounds worth $27.8 billion in 2024.
The squeeze landed hardest at the start of the pipeline. Seed and Series A rounds dropped from 228 to 191, and their combined value from $10.6 billion to $8.7 billion.
| Metric | 2024 | 2025 | H1 2026 |
|---|---|---|---|
| Venture rounds | 461 | 413 | 235 |
| Venture value | $27.8B | $24.6B | $16.3B |
| Seed and Series A rounds | 228 | 191 | not stated |
| Seed and Series A value | $10.6B | $8.7B | not stated |
| Announced licensing R&D value | $190.6B | $250.2B | $166.7B |
Source: J.P. Morgan Biopharma Licensing and Venture Reports, Q4 2025 edition (full-year 2024 and 2025) and Q2 2026 edition (H1 2026), powered by DealForma.
Biotechnology Market Deal Activity In 2026
Mergers and acquisitions ran ahead of venture capital in the first half of 2026. J.P. Morgan recorded $96 billion across 80 biopharma deals, including $55.1 billion from 48 deals in the second quarter.
Upfront cash made up 6% of total announced licensing value in H1 2026, so most of the headline $166.7 billion sits in milestones rather than cash at signing.
How Many New Drugs Did The FDA Approve?
The FDA’s Center for Drug Evaluation and Research approved 46 novel drugs in 2025, down from 50 in 2024. The 2025 cohort split into 34 new molecular entities and 12 biologics.
Rare disease dominated. Of the 46 approvals, 25 carried orphan drug designation and 14 were for cancer.
Source: FDA Center for Drug Evaluation and Research, novel drug approvals by calendar year, 2021–2025.
Biotechnology Market Pipeline: Gene, Cell And RNA Therapies
Regulators cleared eight new advanced therapies worldwide in the second quarter of 2026 — five gene therapies, one RNA therapy and two non-genetically modified cell therapies. That brings global running totals to 46 approved gene therapies, 37 RNA therapies and 76 non-genetically modified cell therapies.
The development pipeline held 4,487 therapies from preclinical through pre-registration in Q2 2026. Gene therapies account for 2,217 of those, or 49%.
Source: ASGCT/Citeline Gene, Cell & RNA Therapy Landscape Report, Q2 2026 (published July 2026), gene therapy pipeline by development stage.
The preclinical layer shrank through 2025 and turned back up in 2026. Phase I, II and III counts rose in every one of the five quarters shown.
CAR-T remains the dominant engineering approach inside the genetically modified cell therapy pipeline, and 81% of CAR-T programmes target cancer.
Source: ASGCT/Citeline Gene, Cell & RNA Therapy Landscape Report, Q2 2026, genetically modified cell therapy pipeline by technology.
Early-stage money returned in 2026. Twenty companies raised a combined $500.4 million in seed or Series A rounds in Q2 2026, against three companies raising $197.0 million in Q2 2025.
Source: ASGCT/Citeline Gene, Cell & RNA Therapy Landscape Report, Q2 2026, seed and Series A financings for gene, cell and RNA therapy companies.
Total dealmaking across advanced molecular therapy companies reached 118 transactions in Q2 2026, up 15% from 103 in Q1 2026. Gilead Sciences paid $7.8 billion for Arcellx in Q1 2026; Eli Lilly agreed to buy Kelonia in Q2 for $3.25 billion upfront plus up to $3.75 billion in earn-outs.
Vertex Pharmaceuticals gives a sense of what commercial scale looks like at this stage: 64 patients received CASGEVY infusions during 2025, 30 of them in the fourth quarter.
Biotechnology Market Leaders By 2025 Revenue
Six US-listed biotechnology companies reported full-year 2025 results spanning $1.9 billion to $36.8 billion.
| Company | FY 2025 total revenue | Change vs 2024 |
|---|---|---|
| Amgen | $36.8 billion | +10% |
| Gilead Sciences | $29.4 billion | +2% |
| Regeneron | $14.3 billion | +1% |
| Vertex | $12.0 billion | +9% |
| Biogen | $9.9 billion | +2% |
| Moderna | $1.9 billion | -40% |
Source: company full-year 2025 results announcements, January–February 2026; figures are total revenue as reported by each company.
Amgen reported 14 products above $1 billion in annual sales for 2025. Moderna booked a GAAP net loss of $2.8 billion on its $1.9 billion of revenue.
Roche reports in Swiss francs and sits outside the dollar table. Group sales reached CHF 61.5 billion in 2025, up 7% at constant exchange rates, with the Pharmaceuticals Division at CHF 47.7 billion against CHF 46.2 billion in 2024.
FAQs
How big is the biotechnology market in 2026?
Estimates differ by firm. Precedence Research puts 2026 at $2.02 trillion, Towards Healthcare at $1,962.93 billion, Straits Research at $1,870 billion and Fortune Business Insights at $1,491.5 billion.
Why do biotechnology market size figures shared on Reddit vary so widely?
Because firms define the market differently. Precedence Research counts five applications including bio-agriculture and bio-industries; Polaris Market Research segments by technology, giving DNA sequencing 38.75% of its 2025 total. Scopes differ, so totals do too.
Is the biotech IPO market recovering, as Reddit investing threads often ask?
J.P. Morgan recorded 13 biopharma IPOs raising $5.0 billion in the first half of 2026, a total exceeding every full year from 2022 through 2025. Venture funding reached $16.3 billion across 235 rounds.
How many drugs did the FDA approve in 2025?
CDER approved 46 novel drugs in 2025: 34 new molecular entities and 12 biologics. Twenty-five carried orphan drug designation and 14 treated cancer. The 2024 figure was 50.
Which region holds the largest biotechnology market share?
North America. Its 2025 share ranges from 37.42% at Precedence Research to 43.34% at Fortune Business Insights. Asia Pacific is named the fastest-growing region, at 14.8% a year through 2035 per Precedence Research.
Sources
https://www.precedenceresearch.com/biotechnology-market
https://www.jpmorgan.com/insights/markets-and-economy/outlook/biopharma-medtech-deal-reports
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
